CLINICAL_TRIALS
ClinicalTrials.gov record update
TRastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("TREAT CTC" Trial)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01548677
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:22.384612+00:00
- Published At
- 2019-03-13T00:00:00+00:00
- Record Updated At
- 2019-03-13
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Breast Cancer", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Circulating Tumor Cells"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-03-13"- protocolSection.identificationModule.nctId
"NCT01548677"- protocolSection.identificationModule.officialTitle
"TRastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (\"TREAT CTC\" Trial)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.